Report post
Ahead of 2024, Jefferies' top analyst predicts a biotech boom, citing the Bristol Meyers-Karuna deal as a precursor. Adaptive Biotechnologies CEO offers insights on the company's IPO and pipeline. Cramer suggests a biotech stock with potential to reach over $100 billion upon FDA approval. Stay tuned for the next wave in biotech.

Related articles

The World's Leading Crypto Trading Platform

Get my welcome gifts